Abstract: An embodiment LED driver system comprises a power transistor configured to be selectively activated for generating a driving current for an array of LEDs, the power transistor having a first conduction terminal coupled to the array of LEDs and a second conduction terminal coupled to a reference resistor; an operational amplifier having a non-inverting input for receiving a reference voltage, an inverting input coupled to the second conduction terminal of the power transistor, and an output terminal coupled to a first conduction terminal of a transmission gate having a second conduction terminal coupled to a control terminal of the power transistor and a control terminal for receiving an enable signal; and a slew rate control unit configured to control the slew rate of the driving current.

Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-?4?7 antibody, e.g., vedolizumab, to a human subject in need thereof.

Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.

Abstract: The present invention features, inter alia, methods of treating (a) a patient who has been diagnosed with a hematopoietic cancer or (b) a population of patients who have been diagnosed with a hematopoietic cancer with a fixed dose of tamibarotene or a pharmaceutically acceptable salt thereof. The tamibarotene is administered daily, for a prescribed number of days, at 8-14 (e.g., 12 mg/day) regardless of the patient's weight or body surface area, and may be administered as the sole therapeutic agent or in combination with one or more of the additional therapeutic agents described herein.

Abstract: A method for modulating green character of wine, as well as wine obtainable according to the method also relates to the use of a vine-shoot material as winemaking additive for modulating green character in wine, wherein the vine-shoot material is toasted vine-shoot material. The method includes the steps of providing a vine-shoot material, which is subjected to heating at a predetermined temperature during a period in the range from 30 to 120 minutes; and subjecting a fermentable mixture to fermentation, wherein a determined concentration of the vine-shoot material results from the heating step.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: The invention relates to a resting element with connection to the earth connection of the dwelling, of the type comprising a mattress topper, a bed base, and a latex mattress; where the topper has a means for connecting to the mattress and this, in turn, to the bed base, which finally connects to the earth connection of the dwelling via a universal connection system that incorporates a safety system to avoid overloading the line; and wherein the sheath incorporates a mesh of gold, silver, and organic graphite and silver filament which, together with the connection with the rest of the elements, improves its residual discharge and insulating capacity.

Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.

Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-?4?7 antibody, e.g., vedolizumab, to a human subject in need thereof.

Abstract: The invention provides methods for identifying patients who do not adequately respond to vedolizumab therapy and treating these patients with a personalized treatment approach using vedolizumab.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: The invention provides methods for treating pediatric inflammatory bowel disease patients using vedolizumab.

Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.

Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-?4?7 antibody, e.g., vedolizumab, to a human subject in need thereof.

Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.

Abstract: The invention provides methods for identifying patients who do not adequately respond to vedolizumab therapy and treating these patients with a personalized treatment approach using vedolizumab.

Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Abstract: Antibody formulations are described comprising a mixture of an anti-a4b7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4b7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.